- Joined
- 20 July 2021
- Posts
- 10,972
- Reactions
- 15,238
i was hoping to tip it for the yearly ( and add some more around 50 cents a share ) but it started to lift before the comp. start so went elsewhere
good luck
VIT - Vitura Health
- Thread starter System
- Start date
good luck
- Joined
- 20 July 2021
- Posts
- 10,972
- Reactions
- 15,238
CHANGES TO CLINICAL OPERATIONS
• Physical CDA Clinics on the Gold Coast, Brisbane and Sunshine Coast to close and transition to a 100% telehealth service • Changes deliver significant overhead cost savings, continued quality patient care and a highly scalable business model
• With more than 95% of patient consults by CDA Clinics currently being undertaken via telehealth, these changes are aligned with patient preferences and the rapid adoption of telehealth during the COVID-19 pandemic
• Investment in systems and human capital to continue to support the growth of the business Melbourne, Australia, 16 January 2023 – Cronos Australia Limited (ASX:CAU) (Company) advises that the physical CDA Clinics on the Gold Coast, Brisbane and Sunshine Coast will close by 31 March 2023 and transition to a 100% telehealth service.
These changes deliver significant overhead cost savings to the Company, continued quality patient care and a highly scalable business model.
Currently, more than 95% of all patient consults by CDA Clinics are undertaken via telehealth and the changes respond to patient preferences and the rapid adoption of telehealth during the COVID-19 pandemic. Additionally, the CDA Dispensary at the Gold Coast clinic will cease operations as part of the transition to 100% telehealth.
Patients who were being dispensed medicinal cannabis products at that location will have their scripts filled by one of the 3,200+ partner pharmacies on the CanView platform. With the Company’s continued growth, Cronos intends to run a process to redeploy impacted staff into other roles within the business, where possible.
While there may be a small number of job losses from this process, the Company expects the impact to be minimal. “As the market leader in Australia, we operate in a rapidly evolving industry that demands constant innovation to ensure we continue to serve our patients, prescribers, pharmacies and suppliers in the best possible way.
Moreover, our transition to 100% telehealth will deliver significant cost savings and a scalable business model that allows us to consult with patients nationally not just in the local clinic area. In line with these changes, the Company is committed to investment in systems and human capital to continue to grow the business into the future,” noted Chief Executive Officer, Rodney Cocks.
** ENDS **
i hold CAU
• Physical CDA Clinics on the Gold Coast, Brisbane and Sunshine Coast to close and transition to a 100% telehealth service • Changes deliver significant overhead cost savings, continued quality patient care and a highly scalable business model
• With more than 95% of patient consults by CDA Clinics currently being undertaken via telehealth, these changes are aligned with patient preferences and the rapid adoption of telehealth during the COVID-19 pandemic
• Investment in systems and human capital to continue to support the growth of the business Melbourne, Australia, 16 January 2023 – Cronos Australia Limited (ASX:CAU) (Company) advises that the physical CDA Clinics on the Gold Coast, Brisbane and Sunshine Coast will close by 31 March 2023 and transition to a 100% telehealth service.
These changes deliver significant overhead cost savings to the Company, continued quality patient care and a highly scalable business model.
Currently, more than 95% of all patient consults by CDA Clinics are undertaken via telehealth and the changes respond to patient preferences and the rapid adoption of telehealth during the COVID-19 pandemic. Additionally, the CDA Dispensary at the Gold Coast clinic will cease operations as part of the transition to 100% telehealth.
Patients who were being dispensed medicinal cannabis products at that location will have their scripts filled by one of the 3,200+ partner pharmacies on the CanView platform. With the Company’s continued growth, Cronos intends to run a process to redeploy impacted staff into other roles within the business, where possible.
While there may be a small number of job losses from this process, the Company expects the impact to be minimal. “As the market leader in Australia, we operate in a rapidly evolving industry that demands constant innovation to ensure we continue to serve our patients, prescribers, pharmacies and suppliers in the best possible way.
Moreover, our transition to 100% telehealth will deliver significant cost savings and a scalable business model that allows us to consult with patients nationally not just in the local clinic area. In line with these changes, the Company is committed to investment in systems and human capital to continue to grow the business into the future,” noted Chief Executive Officer, Rodney Cocks.
** ENDS **
i hold CAU
So_Cynical
The Contrarian Averager
- Joined
- 31 August 2007
- Posts
- 7,464
- Reactions
- 1,463
100% online and on the phone, smash them overheads, at first it seems a little wrong but 95% to 100% is not a big leap.
- Joined
- 20 July 2021
- Posts
- 10,972
- Reactions
- 15,238
the market didn't like it ( finished down more than 10%)
however i do wonder how the prescription system will go without face-to-face consultations ,
will they give commissions ( or some other rewards ) to GPs , or maybe psychologists
risking the same flaws as the general pharmaceutical industry
i guess time will tell
- Joined
- 20 July 2021
- Posts
- 10,972
- Reactions
- 15,238
ASX ANNOUNCEMENT
CHANGE OF NAME TO VITURA HEALTH LIMITED
6 FEBRUARY 2023
• Cronos Australia Limited (ASX:CAU) (Company) has changed its name to Vitura Health
Limited
• The Company anticipates that its ASX code will be updated to VIT from opening of
trade on Wednesday, 8 February 2023
• No change to brands in the Vitura Health portfolio, including CanView, Burleigh Heads
Cannabis, CDA Clinics, Cannadoc and Adaya
Melbourne, Australia - At its 2022 Annual General Meeting (AGM) on 29 November 2022,
the Company sought the approval of its shareholders to change the name of the Company
to Vitura Health Limited. Since its merger with CDA Health Pty Ltd., the Company has
worked to integrate the two businesses into one cohesive, high performing company. The
Board believes that this integration will be deepened by the Group adopting a new name
that reflects the vision, values and aspirations of the merged Company, rather than being tied
to a name that more closely reflected the Cronos Australia pre-Merger business. The
resolution to approve the name change was overwhelmingly supported by the shareholders,
with more than 99.7% of all votes cast in respect of the resolution supporting the change.
The Company advises that the Australian Securities and Investments Commission has today
altered the details of the Company’s registration to reflect the change of name. Accordingly,
effective today, the Company’s name has been changed to Vitura Health Limited. A copy
of the Certificate of the Registration of a Company showing the change of name is attached.
The Company anticipates that it will commence trading on the ASX under the name Vitura
Health Limited and the new ASX code VIT, as from the opening of trade on 8 February 2023.
There are no changes to the brands in the Vitura Health portfolio, including CanView,
Burleigh Heads Cannabis, CDA Clinics, Cannadoc and Adaya.
In announcing the Company’s change of name, Chief Executive Officer, Rodney Cocks said:
“I am excited and proud to announce the Company’s new name and corporate branding
which embodies the direction we are taking and we are confident will be well received by
all of our stakeholders, including our employees. We look forward to continuing to grow
under the new Vitura Health brand and delivering on our strategic objectives for our patients,
prescribers, pharmacists, suppliers and shareholders”.
** ENDS **
i hold CAU
and that is how you get me to cancel my top-up order
will wait for the official ticker code change
and CONSIDER an order 30% lower in the resultant confusion
seems to be just spraying money about ( to me )
CHANGE OF NAME TO VITURA HEALTH LIMITED
6 FEBRUARY 2023
• Cronos Australia Limited (ASX:CAU) (Company) has changed its name to Vitura Health
Limited
• The Company anticipates that its ASX code will be updated to VIT from opening of
trade on Wednesday, 8 February 2023
• No change to brands in the Vitura Health portfolio, including CanView, Burleigh Heads
Cannabis, CDA Clinics, Cannadoc and Adaya
Melbourne, Australia - At its 2022 Annual General Meeting (AGM) on 29 November 2022,
the Company sought the approval of its shareholders to change the name of the Company
to Vitura Health Limited. Since its merger with CDA Health Pty Ltd., the Company has
worked to integrate the two businesses into one cohesive, high performing company. The
Board believes that this integration will be deepened by the Group adopting a new name
that reflects the vision, values and aspirations of the merged Company, rather than being tied
to a name that more closely reflected the Cronos Australia pre-Merger business. The
resolution to approve the name change was overwhelmingly supported by the shareholders,
with more than 99.7% of all votes cast in respect of the resolution supporting the change.
The Company advises that the Australian Securities and Investments Commission has today
altered the details of the Company’s registration to reflect the change of name. Accordingly,
effective today, the Company’s name has been changed to Vitura Health Limited. A copy
of the Certificate of the Registration of a Company showing the change of name is attached.
The Company anticipates that it will commence trading on the ASX under the name Vitura
Health Limited and the new ASX code VIT, as from the opening of trade on 8 February 2023.
There are no changes to the brands in the Vitura Health portfolio, including CanView,
Burleigh Heads Cannabis, CDA Clinics, Cannadoc and Adaya.
In announcing the Company’s change of name, Chief Executive Officer, Rodney Cocks said:
“I am excited and proud to announce the Company’s new name and corporate branding
which embodies the direction we are taking and we are confident will be well received by
all of our stakeholders, including our employees. We look forward to continuing to grow
under the new Vitura Health brand and delivering on our strategic objectives for our patients,
prescribers, pharmacists, suppliers and shareholders”.
** ENDS **
i hold CAU
and that is how you get me to cancel my top-up order
will wait for the official ticker code change
and CONSIDER an order 30% lower in the resultant confusion
seems to be just spraying money about ( to me )
- Joined
- 27 June 2010
- Posts
- 4,147
- Reactions
- 309
On February 8th, 2023, Cronos Australia Limited (CAU) changed its name and ASX code to Vitura Health Limited (VIT).
- Joined
- 21 August 2008
- Posts
- 2,784
- Reactions
- 8,524
@Als2own I've just noticed CAU - Cronos Australia has changed it's Name and Code to VIT - VITURA HEALTH LTD. Did you know?
- Joined
- 20 July 2021
- Posts
- 10,972
- Reactions
- 15,238
VITURA HEALTH TO ACQUIRE 24/7 NATIONWIDE TELEHEALTH BUSINESS - DOCTORS ON DEMAND 19 OCTOBER 2023
Melbourne, Australia – Vitura Health Limited (ASX: VIT) (Vitura and Company) is pleased to announce that it has entered into binding agreements (Agreements) to acquire the entire issued capital of Doctors on Demand Pty Ltd ACN 163 312 570 (DoD) for an aggregate consideration of $25 million comprising an upfront cash component, a deferred cash component and an equity component (Acquisition). The Acquisition is expected to complete on or around 26 October 2023 (subject to the satisfaction or waiver of the limited conditions precedent described below) (Completion).
About Doctors on Demand Founded in 2015 by Brisbane pharmacists John Martin and John Neilson, DoD is a private Australian company that operates a leading digital platform to facilitate the treatment of patients and the provision of telehealth, healthcare and related services by Australian registered healthcare practitioners via videoconference. Those healthcare practitioners offer the telehealth services 24 hours a day, 365 days a year via DoD’s proprietary platform through the provision of online consultations with patients by virtually examining and taking the medical history of the patient via videoconference and other technologies.
As telehealth pioneers, the foundations of DoD predate the COVID-19 pandemic and the widespread adoption of telehealth as a medical consultation format. Since that time, DoD’s technology has increased in scale and sophistication, with key business metrics achieved including:
• 120+ doctors that currently treat patients on the DoD platform
• Record number of consults in a 24-hour period during September 2023, being 1,040 consults
i hold VIT
well that was an unexpected turn ( for me )
and something that is bright green in the portfolio today
Melbourne, Australia – Vitura Health Limited (ASX: VIT) (Vitura and Company) is pleased to announce that it has entered into binding agreements (Agreements) to acquire the entire issued capital of Doctors on Demand Pty Ltd ACN 163 312 570 (DoD) for an aggregate consideration of $25 million comprising an upfront cash component, a deferred cash component and an equity component (Acquisition). The Acquisition is expected to complete on or around 26 October 2023 (subject to the satisfaction or waiver of the limited conditions precedent described below) (Completion).
About Doctors on Demand Founded in 2015 by Brisbane pharmacists John Martin and John Neilson, DoD is a private Australian company that operates a leading digital platform to facilitate the treatment of patients and the provision of telehealth, healthcare and related services by Australian registered healthcare practitioners via videoconference. Those healthcare practitioners offer the telehealth services 24 hours a day, 365 days a year via DoD’s proprietary platform through the provision of online consultations with patients by virtually examining and taking the medical history of the patient via videoconference and other technologies.
As telehealth pioneers, the foundations of DoD predate the COVID-19 pandemic and the widespread adoption of telehealth as a medical consultation format. Since that time, DoD’s technology has increased in scale and sophistication, with key business metrics achieved including:
• 120+ doctors that currently treat patients on the DoD platform
• Record number of consults in a 24-hour period during September 2023, being 1,040 consults
i hold VIT
well that was an unexpected turn ( for me )
and something that is bright green in the portfolio today
bluekelah
StockFan
- Joined
- 25 March 2013
- Posts
- 246
- Reactions
- 539
have PMed you again
- Joined
- 20 July 2021
- Posts
- 10,972
- Reactions
- 15,238
Melbourne, Australia –
Vitura Health Limited (ASX:VIT) (Vitura or Company) announces that Code4 Cannabis Pty Ltd (C4C) has notified Vitura’s wholly-owned subsidiary Canview Pty Ltd that C4C does not intend to extend the Services Agreement pursuant to which Vitura exclusively licenses software used as part of the CanView platform (Software) beyond its expiry date of 10 August 2024.
The notification follows Vitura raising a number of issues with C4C in relation to their conduct.
Vitura has exercised its right under the Services Agreement to enact a 15 month transitional period from 10 August 2024.
Vitura (through Canview Pty Ltd) will continue to be the exclusive licensee of the Software until 10 November 2025.
Vitura will assess its options with respect to the CanView ecosystem, which may include implementing alternate software prior to 10 November 2025 or exercising its option under the Services Agreement to acquire C4C.
Furthermore, under the Services Agreement, C4C will be prohibited from licensing the Software to any third party for a further 12 months following the end of the transitional period.
i hold VIT
Vitura Health Limited (ASX:VIT) (Vitura or Company) announces that Code4 Cannabis Pty Ltd (C4C) has notified Vitura’s wholly-owned subsidiary Canview Pty Ltd that C4C does not intend to extend the Services Agreement pursuant to which Vitura exclusively licenses software used as part of the CanView platform (Software) beyond its expiry date of 10 August 2024.
The notification follows Vitura raising a number of issues with C4C in relation to their conduct.
Vitura has exercised its right under the Services Agreement to enact a 15 month transitional period from 10 August 2024.
Vitura (through Canview Pty Ltd) will continue to be the exclusive licensee of the Software until 10 November 2025.
Vitura will assess its options with respect to the CanView ecosystem, which may include implementing alternate software prior to 10 November 2025 or exercising its option under the Services Agreement to acquire C4C.
Furthermore, under the Services Agreement, C4C will be prohibited from licensing the Software to any third party for a further 12 months following the end of the transitional period.
i hold VIT
- Joined
- 20 July 2021
- Posts
- 10,972
- Reactions
- 15,238
bought a few extra @ 22.5 cents ( missing the bottom )
will watch and think if i should add more say around 20 cents
not the Xmas gem i was hoping for , but i often grab what i can get
will watch and think if i should add more say around 20 cents
not the Xmas gem i was hoping for , but i often grab what i can get
So_Cynical
The Contrarian Averager
- Joined
- 31 August 2007
- Posts
- 7,464
- Reactions
- 1,463
VIT as the leading Cannabis stock on the ASX will continue to benefit from the continuing normalisation of cannabis usage.
- Joined
- 20 July 2021
- Posts
- 10,972
- Reactions
- 15,238
is veering towards a tele-heath service , whether that is a good move , well time will tell
but it had been previously making a profit and starting to look like a div. payer ( but have been fooled before , elsewhere )
| Balance Date | Dividend Type | Cents per share | Ccy | Franked % | Ex-Dividend Date | Books Close Date | Pay Date |
|---|---|---|---|---|---|---|---|
| 30/06/2023 | Final | 1.000 | AUD | 100.00 | 04/09/2023 | 05/09/2023 | 28/09/2023 |
| 30/06/2022 | Final | AUD | 100.00 | - | 19/09/2022 | 11/10/2022 | |
| 30/06/2016 | Final | 2.960 | AUD | 0.00 | 05/09/2016 | 06/09/2016 | 30/09/2016 |
| 31/12/2015 | Interim | 1.690 | AUD | 0.00 | 02/03/2016 | 04/03/2016 | 31/03/2016 |
- Joined
- 20 July 2021
- Posts
- 10,972
- Reactions
- 15,238
Vitura Health announced the addition of prescription only smoking cessation products on CanView to support patients in their journey to quit smoking and reduce their dependency on nicotine.
These products are also known as nicotine vaping products.
i hold VIT
will try to find the ASX release
am trying to decide if to cancel my low-ball ( top up ) order
These products are also known as nicotine vaping products.
i hold VIT
will try to find the ASX release
am trying to decide if to cancel my low-ball ( top up ) order
- Joined
- 20 July 2021
- Posts
- 10,972
- Reactions
- 15,238
VITURA COMPLETES BUILD OUT OF SMOKING CESSATION OFFERING ADDING NEW PRODUCT VERTICAL TO CANVIEW
9 JANUARY 2024 Melbourne, Australia –
Vitura Health Limited (ASX: VIT) (Vitura and Company) is pleased to announce the addition of prescription only smoking cessation products on CanView in order to support patients in their journey to quit smoking and reduce their dependency on nicotine.
These products are also known as nicotine vaping products (NVPs). Sweeping changes announced by the Therapeutic Goods Administration On 15 December 2023, the Therapeutics Goods Administration (TGA) announced sweeping changes on how NVPs can be accessed.
The Australian government has outlined its plan to eradicate NVPs from the market that are not accessed via a prescription as part of a medical strategy to support patients in ceasing smoking or reducing their dependency on nicotine.
From 1 January 2024 1 , the importation of non-prescription disposable NVPs is prohibited, subject to extremely limited exceptions (requiring a license and permit).
The ban will apply to disposable NVPs irrespective of nicotine content or therapeutic claims. This means that it is unlawful to import non-prescription disposable NVPs from 1 January 2024.
Also, from 1 January 2024, doctors and nurse practitioners will be able to prescribe NVPs for smoking cessation or the management of nicotine dependence without applying to the TGA for pre-authority or approval through the Special Access Scheme C pathway.
This will reduce the administrative burden on prescribers while facilitating legitimate access to prescription only therapeutic NVPs as part of a prescription only medical strategy to support patients in ceasing smoking or reducing their dependency on nicotine.
Build out of the Smoking Cessation offering on CanView and market opportunity In support of the recent and planned changes by the TGA, which is aimed at making all NVPs available only via a medical prescription and dispensed only by a pharmacist, Vitura has added this new vertical to its product supply and distribution ecosystem, CanView.
The Company has signed exclusive agreements with a number of leading 1 https://www.tga.gov.au/products/unapproved-therapeutic-goods/vaping-hub suppliers who currently provide prescription only NVPs to the Australian market which meet the TGA quality standards for supply to patients.
Vitura will utilise its proven first to market approach and expertise demonstrated with medicinal cannabis and psychedelics in the unregistered therapeutic goods market to replicate that success and to support patients in their journey to quit smoking and reduce their dependency on nicotine.
A number of smoking cessation products from a range of leading brands are currently available to be ordered by pharmacies on Vitura’s product supply and distribution ecosystem, CanView.
Analysts estimate that the Australian nicotine replacement therapy market is worth $265 million in 2024 2 however, this does not take account of the recent TGA changes that could potentially expand the market further.
Comments on the introduction of a Smoking Cessation offering on CanView “In another milestone for Vitura, as a leading digital health company, we are extremely proud to have secured supply and built out the new vertical for the distribution of smoking cessation products on our product supply and distribution ecosystem, CanView.
We applaud the TGA for the changes that have been implemented with respect to all vaping products, and we look forward to supporting patients in their journey to quit smoking and reduce their dependency on nicotine.
The smoking cessation product offering is another demonstration of the value that can be created on our CanView ecosystem, further increasing the network effect experienced by those using it.
The roll out builds on the wide range of medicinal cannabis and psychedelic products now available through the CanView ecosystem and paves the way for further verticals to be added. We will continue to update our shareholders on the ongoing success of the smoking cessation offering on CanView in a market that is estimated to be in excess of $250m in size, and set to grow further on the back of the TGA changes to NVPs in the Australian market,” Vitura's Chief Executive Officer and Executive Director, Rodney Cocks said.
** ENDS **
i hold VIT
what a clown show ( the TGA )
am still not convinced of the safety of vapes compared to patches
to me this isn't a big deal , although leveraged to their new tele-health adventure it may help that succeed
i will stay quietly cautious here
9 JANUARY 2024 Melbourne, Australia –
Vitura Health Limited (ASX: VIT) (Vitura and Company) is pleased to announce the addition of prescription only smoking cessation products on CanView in order to support patients in their journey to quit smoking and reduce their dependency on nicotine.
These products are also known as nicotine vaping products (NVPs). Sweeping changes announced by the Therapeutic Goods Administration On 15 December 2023, the Therapeutics Goods Administration (TGA) announced sweeping changes on how NVPs can be accessed.
The Australian government has outlined its plan to eradicate NVPs from the market that are not accessed via a prescription as part of a medical strategy to support patients in ceasing smoking or reducing their dependency on nicotine.
From 1 January 2024 1 , the importation of non-prescription disposable NVPs is prohibited, subject to extremely limited exceptions (requiring a license and permit).
The ban will apply to disposable NVPs irrespective of nicotine content or therapeutic claims. This means that it is unlawful to import non-prescription disposable NVPs from 1 January 2024.
Also, from 1 January 2024, doctors and nurse practitioners will be able to prescribe NVPs for smoking cessation or the management of nicotine dependence without applying to the TGA for pre-authority or approval through the Special Access Scheme C pathway.
This will reduce the administrative burden on prescribers while facilitating legitimate access to prescription only therapeutic NVPs as part of a prescription only medical strategy to support patients in ceasing smoking or reducing their dependency on nicotine.
Build out of the Smoking Cessation offering on CanView and market opportunity In support of the recent and planned changes by the TGA, which is aimed at making all NVPs available only via a medical prescription and dispensed only by a pharmacist, Vitura has added this new vertical to its product supply and distribution ecosystem, CanView.
The Company has signed exclusive agreements with a number of leading 1 https://www.tga.gov.au/products/unapproved-therapeutic-goods/vaping-hub suppliers who currently provide prescription only NVPs to the Australian market which meet the TGA quality standards for supply to patients.
Vitura will utilise its proven first to market approach and expertise demonstrated with medicinal cannabis and psychedelics in the unregistered therapeutic goods market to replicate that success and to support patients in their journey to quit smoking and reduce their dependency on nicotine.
A number of smoking cessation products from a range of leading brands are currently available to be ordered by pharmacies on Vitura’s product supply and distribution ecosystem, CanView.
Analysts estimate that the Australian nicotine replacement therapy market is worth $265 million in 2024 2 however, this does not take account of the recent TGA changes that could potentially expand the market further.
Comments on the introduction of a Smoking Cessation offering on CanView “In another milestone for Vitura, as a leading digital health company, we are extremely proud to have secured supply and built out the new vertical for the distribution of smoking cessation products on our product supply and distribution ecosystem, CanView.
We applaud the TGA for the changes that have been implemented with respect to all vaping products, and we look forward to supporting patients in their journey to quit smoking and reduce their dependency on nicotine.
The smoking cessation product offering is another demonstration of the value that can be created on our CanView ecosystem, further increasing the network effect experienced by those using it.
The roll out builds on the wide range of medicinal cannabis and psychedelic products now available through the CanView ecosystem and paves the way for further verticals to be added. We will continue to update our shareholders on the ongoing success of the smoking cessation offering on CanView in a market that is estimated to be in excess of $250m in size, and set to grow further on the back of the TGA changes to NVPs in the Australian market,” Vitura's Chief Executive Officer and Executive Director, Rodney Cocks said.
** ENDS **
i hold VIT
what a clown show ( the TGA )
am still not convinced of the safety of vapes compared to patches
to me this isn't a big deal , although leveraged to their new tele-health adventure it may help that succeed
i will stay quietly cautious here
- Joined
- 20 July 2021
- Posts
- 10,972
- Reactions
- 15,238
AGREEMENT EXECUTED WITH WHOLELIFE PHARMACY GROUP – ONE OF AUSTRALIA’S LEADING MEDICINAL CANNABIS DISPENSING NETWORKS HIGHLIGHTS
● Vitura Health and one of Australia’s leading pharmacy and health food groups, WholeLife Pharmacy Pty Ltd (WholeLife), have executed a technology and product supply services agreement (Agreement).
● Under the terms of the Agreement, Vitura will provide the WholeLife Pharmacy & Healthfoods network with a WholeLife branded version of the CanView platform for use by the Group’s extensive network of pharmacies, patients and partner prescribers.
● WholeLife currently works in partnership with one of the nation’s leading holistic health clinics, One Health Clinics Australia based in Cairns, which also provides face-to-face and telehealth consultations to 14,000 patients nationwide.
● The WholeLife branded CanView platform will provide partner prescribers access to prescribe a wide range of products via the CanView platform’s streamlined e-prescribing functionality, supporting dispensing via the WholeLife Pharmacy & Healthfoods group.
● WholeLife Pharmacy & Healthfoods dispensaries will be able to receive prescriptions from the CanView ecosystem and dispense products through the WholeLife branded CanView platform. WholeLife currently has 22 pharmacies with 10 more pharmacies expected to be opened by the end of calendar 2024.
● The WholeLife branded version of CanView is expected to increase the volume of products prescribed and distributed through the CanView platform, and the number of patients and prescribers registered and using the platform’s functionality.
● WholeLife patients will benefit from registering on the WholeLife branded CanView platform and having access to the features of the patient app, including the ability to have all of their relevant prescriptions stored in one place, in app payments and express home delivery of CanView listed products.
● The WholeLife Agreement is further validation of Vitura’s market leading technology and distribution ecosystem, being the second branded deployment of the platform with the backing of two state-of-the-art distribution centres.
22 January 2024 Melbourne, Australia – Vitura Health Limited (ASX: VIT) (Vitura and Company) is pleased to announce the execution of a new Services Agreement with Australian-based WholeLife Pharmacy Pty Limited (WholeLife), incorporating the network of the WholeLife Pharmacy & Healthfoods franchised stores.
Under the terms of the Agreement, Vitura will provide WholeLife, including its franchisees, with a WholeLife branded version of the CanView platform for exclusive use by WholeLife’s network of pharmacies, patients and partnered prescribing doctors and practitioners.
The CanView platform will provide the WholeLife pharmacy network with significant benefits, including increases in workflow efficiencies across all participants in the pharmacy group’s ecosystem, seamless compliance reporting, and a turnkey operating solution for existing and future WholeLife franchisees.
The Agreement provides Vitura with exposure to WholeLife’s growing pharmacy network of 22 stores, in high foot traffic locations and another 10 planned to be opened during 2024.
WholeLife currently works in partnership with one of the nation’s leading holistic health clinics, One Health Clinics Australia based in Cairns, which provides local face-to-face and nationwide telehealth consultations specialising in alternative and natural therapies.
Working alongside One Health Clinics Australia, the Wholelife Pharmacy network provides medication access to 14,000 patients nationwide.
As part of the Agreement, Vitura, via its wholly owned subsidiary Burleigh Heads Cannabis Pty Ltd), will also distribute WholeLife’s newly branded products which will be sold and distributed via the WholeLife branded CanView platform.
The WholeLife branded version of CanView is expected to increase the volume of products prescribed and distributed through the CanView platform, and the number of patients and prescribers registered and using the platform’s functionality.
The WholeLife Agreement is further validation of Vitura’s market leading technology and distribution ecosystem, being the second branded deployment of the platform with the backing of two state-of-the-art distribution centres.
Comments on the Agreement In announcing the Agreement, Vitura Health CEO and Executive Director, Rodney Cocks, said: “We are very pleased to have executed the agreement for technology and product supply via a WholeLife branded version of our CanView platform with Frank and Vince Pappalardo as well as the wider WholeLife business.
Since launching the new prescriber and patient functionality of our platform last year, we are excited to see the CanView platform coupled with the nationally scaled distribution operations being favoured as the complete end-to-end solution within the industry.
We look forward to working closely with WholeLife to build on their leading position in the industry providing better service through leveraging the many benefits of the CanView platform.” Frank Pappalardo, co-Founder and Director of WholeLife Pharmacy Pty Ltd said: “We are thrilled to partner with Vitura as a technology and product supply partner including integrating their industry leading CanView platform into our greater WholeLife ecosystem.
This agreement provides an end-to-end solution for our patients supporting them to manage their prescriptions and gain access to a wider range of medicines.
We believe this groundbreaking agreement supports the evolving needs of our customer base.” Damian Young, CEO, WholeLife Pharmacy Pty Ltd said: “Partnering with Vitura will help enhance the workflow efficiencies and compliance reporting for our stores while also supporting our patients with a range of alternative health options and natural therapies that align with the WholeLife brand’s holistic vision.
CanView provides a turnkey solution for our existing and new franchisees supporting them to deliver positive patient outcomes.”
** ENDS **
i hold VIT
i like this ann better than the previous one , but am staying cautious , i have been ravaged by data breaches in companies i have held before , and this increases the IT to more exposure
● Vitura Health and one of Australia’s leading pharmacy and health food groups, WholeLife Pharmacy Pty Ltd (WholeLife), have executed a technology and product supply services agreement (Agreement).
● Under the terms of the Agreement, Vitura will provide the WholeLife Pharmacy & Healthfoods network with a WholeLife branded version of the CanView platform for use by the Group’s extensive network of pharmacies, patients and partner prescribers.
● WholeLife currently works in partnership with one of the nation’s leading holistic health clinics, One Health Clinics Australia based in Cairns, which also provides face-to-face and telehealth consultations to 14,000 patients nationwide.
● The WholeLife branded CanView platform will provide partner prescribers access to prescribe a wide range of products via the CanView platform’s streamlined e-prescribing functionality, supporting dispensing via the WholeLife Pharmacy & Healthfoods group.
● WholeLife Pharmacy & Healthfoods dispensaries will be able to receive prescriptions from the CanView ecosystem and dispense products through the WholeLife branded CanView platform. WholeLife currently has 22 pharmacies with 10 more pharmacies expected to be opened by the end of calendar 2024.
● The WholeLife branded version of CanView is expected to increase the volume of products prescribed and distributed through the CanView platform, and the number of patients and prescribers registered and using the platform’s functionality.
● WholeLife patients will benefit from registering on the WholeLife branded CanView platform and having access to the features of the patient app, including the ability to have all of their relevant prescriptions stored in one place, in app payments and express home delivery of CanView listed products.
● The WholeLife Agreement is further validation of Vitura’s market leading technology and distribution ecosystem, being the second branded deployment of the platform with the backing of two state-of-the-art distribution centres.
22 January 2024 Melbourne, Australia – Vitura Health Limited (ASX: VIT) (Vitura and Company) is pleased to announce the execution of a new Services Agreement with Australian-based WholeLife Pharmacy Pty Limited (WholeLife), incorporating the network of the WholeLife Pharmacy & Healthfoods franchised stores.
Under the terms of the Agreement, Vitura will provide WholeLife, including its franchisees, with a WholeLife branded version of the CanView platform for exclusive use by WholeLife’s network of pharmacies, patients and partnered prescribing doctors and practitioners.
The CanView platform will provide the WholeLife pharmacy network with significant benefits, including increases in workflow efficiencies across all participants in the pharmacy group’s ecosystem, seamless compliance reporting, and a turnkey operating solution for existing and future WholeLife franchisees.
The Agreement provides Vitura with exposure to WholeLife’s growing pharmacy network of 22 stores, in high foot traffic locations and another 10 planned to be opened during 2024.
WholeLife currently works in partnership with one of the nation’s leading holistic health clinics, One Health Clinics Australia based in Cairns, which provides local face-to-face and nationwide telehealth consultations specialising in alternative and natural therapies.
Working alongside One Health Clinics Australia, the Wholelife Pharmacy network provides medication access to 14,000 patients nationwide.
As part of the Agreement, Vitura, via its wholly owned subsidiary Burleigh Heads Cannabis Pty Ltd), will also distribute WholeLife’s newly branded products which will be sold and distributed via the WholeLife branded CanView platform.
The WholeLife branded version of CanView is expected to increase the volume of products prescribed and distributed through the CanView platform, and the number of patients and prescribers registered and using the platform’s functionality.
The WholeLife Agreement is further validation of Vitura’s market leading technology and distribution ecosystem, being the second branded deployment of the platform with the backing of two state-of-the-art distribution centres.
Comments on the Agreement In announcing the Agreement, Vitura Health CEO and Executive Director, Rodney Cocks, said: “We are very pleased to have executed the agreement for technology and product supply via a WholeLife branded version of our CanView platform with Frank and Vince Pappalardo as well as the wider WholeLife business.
Since launching the new prescriber and patient functionality of our platform last year, we are excited to see the CanView platform coupled with the nationally scaled distribution operations being favoured as the complete end-to-end solution within the industry.
We look forward to working closely with WholeLife to build on their leading position in the industry providing better service through leveraging the many benefits of the CanView platform.” Frank Pappalardo, co-Founder and Director of WholeLife Pharmacy Pty Ltd said: “We are thrilled to partner with Vitura as a technology and product supply partner including integrating their industry leading CanView platform into our greater WholeLife ecosystem.
This agreement provides an end-to-end solution for our patients supporting them to manage their prescriptions and gain access to a wider range of medicines.
We believe this groundbreaking agreement supports the evolving needs of our customer base.” Damian Young, CEO, WholeLife Pharmacy Pty Ltd said: “Partnering with Vitura will help enhance the workflow efficiencies and compliance reporting for our stores while also supporting our patients with a range of alternative health options and natural therapies that align with the WholeLife brand’s holistic vision.
CanView provides a turnkey solution for our existing and new franchisees supporting them to deliver positive patient outcomes.”
** ENDS **
i hold VIT
i like this ann better than the previous one , but am staying cautious , i have been ravaged by data breaches in companies i have held before , and this increases the IT to more exposure
- Joined
- 20 July 2021
- Posts
- 10,972
- Reactions
- 15,238
SERVICES AGREEMENT WITH CODE4 CANNABIS
23 APRIL 2024
Melbourne, Australia – The Board of Vitura Health Limited (ASX: VIT) (Company or Vitura), a leading digital health platform business, advises that it has received confirmation from Code4 Cannabis Pty. Ltd. (C4C) of its intention to terminate its Services Agreement with Vitura’s wholly-owned subsidiary Canview Pty.
Ltd. (Canview), to be effective from 29 April 2024. On 27 December 2023, the Company announced that C4C had notified that C4C does not intend to extend the Services Agreement pursuant to which Vitura exclusively licenses software used as part of the Canview platform (Software) beyond its expiry date of 10 August 2024, and that Vitura had exercised its right under the Services Agreement to enact a 15-month transitional period until 10 November 2025.
Vitura and Canview do not agree that C4C is entitled to terminate the Services Agreement and has advised C4C accordingly.
Vitura and Canview have now issued proceedings to restrain C4C from withholding services.
The proceedings will be heard in the Supreme Court of Queensland in Brisbane on Friday, 26 April 2024. In the event that C4C ceases to provide services under the Services Contract from 29 April 2024, as threatened, and given the limited time to implement alternative arrangements, it is likely that there will be a material disruption to Vitura’s operations, which may not be fully addressed by the implementation of its business continuity plans.
Vitura will keep the market updated in accordance with its continuous disclosure obligations.
** ENDS **
i hold VIT
dropped below 10 cents for a while this morning
is this a top u opportunity ?
hmmm
23 APRIL 2024
Melbourne, Australia – The Board of Vitura Health Limited (ASX: VIT) (Company or Vitura), a leading digital health platform business, advises that it has received confirmation from Code4 Cannabis Pty. Ltd. (C4C) of its intention to terminate its Services Agreement with Vitura’s wholly-owned subsidiary Canview Pty.
Ltd. (Canview), to be effective from 29 April 2024. On 27 December 2023, the Company announced that C4C had notified that C4C does not intend to extend the Services Agreement pursuant to which Vitura exclusively licenses software used as part of the Canview platform (Software) beyond its expiry date of 10 August 2024, and that Vitura had exercised its right under the Services Agreement to enact a 15-month transitional period until 10 November 2025.
Vitura and Canview do not agree that C4C is entitled to terminate the Services Agreement and has advised C4C accordingly.
Vitura and Canview have now issued proceedings to restrain C4C from withholding services.
The proceedings will be heard in the Supreme Court of Queensland in Brisbane on Friday, 26 April 2024. In the event that C4C ceases to provide services under the Services Contract from 29 April 2024, as threatened, and given the limited time to implement alternative arrangements, it is likely that there will be a material disruption to Vitura’s operations, which may not be fully addressed by the implementation of its business continuity plans.
Vitura will keep the market updated in accordance with its continuous disclosure obligations.
** ENDS **
i hold VIT
dropped below 10 cents for a while this morning
is this a top u opportunity ?
hmmm
- Joined
- 20 July 2021
- Posts
- 10,972
- Reactions
- 15,238
Vitura Health Limited (ASX: VIT)
Vitura Health Limited (ASX: VIT)
Company Information About Vitura Health Limited (ASX: VIT) Vitura Health Limited is a digital health company with a focus on various health-related businesses. It operates in three main segments. The Medical segment is involved in selling and distributing medical cannabis products. The Clinics...
thebull.com.au
i hold VIT
am still watching to see how this 'digital health ' plays out
- Joined
- 20 July 2021
- Posts
- 10,972
- Reactions
- 15,238
VITURA STRATEGY RESET
22 MAY 2024
Melbourne, Australia – The Board of Vitura Health Limited (ASX: VIT) (Company), a leading digital health platform business, has today announced that its new Chair, Robert Iervasi, has completed a review of the strategic direction of Vitura.
This review was undertaken by Mr Iervasi since joining the Board in February 2024 in response to the Company’s operational and financial performance, which is currently below the expectations of the Board and Shareholders.
As an outcome of this review, the Board of Vitura has agreed that a reset of the Company’s strategy is required to enable the sustainable growth of Vitura and improve financial performance through diversification and execution excellence.
As part of this reset, Vitura will focus on:
1. Delivery of its vision of offering healthcare platforms that connect patients and physicians at every stage of the healthcare journey from consultation (Doctors on Demand and CDA Clinics) to enabling prescribing and dispensing (Canview) through a growing network of pharmacy partners.
2. Increasing customer retention and acquisition through expansion of its privileged doctor and clinic networks.
3. Extending its offering through new patient care verticals and B2B partnerships.
4. Optimising patient experience to grow lifetime value through increasing the number and volume of services and medications purchased, and driving retention of patients over their lifetime, as well as enhancing the quality-of-service levels to patients.
5. Enhancing the Doctors on Demand and Canview platforms to provide a best-in-class digital health experience for patients and partners. 6. Improving the Company’s financial performance focusing on revenue growth drivers, enhanced margins, and tighter control of the cost base.
The Chair of the Board, Robert Iervasi said: “I am convinced of the significant opportunity we have at Vitura and believe this reset of our strategy will enable a new growth phase for the business and address many of the challenges we’ve experienced so far this financial year. “We are market leaders in many of the categories in which we operate and are on a pathway to further expand our categories and channels to offer an end-to-end digital health business that will capitalise on high-demand patient needs, initially in the areas of smoking cessation, medicated weight loss management, and women’s and men’s health.
“This diversification of our business should enable us to return to a strong growth profile and deliver a truly enhanced healthcare experience to current and prospective patients throughout their lifetimes.
“I look forward to communicating with shareholders to share what is a much clearer and focussed strategy over the coming months.
The fundamentals of Vitura are strong and I have every confidence in the Company’s future success to reach its full potential which we are now well positioned to unlock.”
Environment for change Vitura has operated a successful business for many years delivering strong financial and operational performance.
The foundations of the Vitura business remain solid but overall performance has been eroded because of increased competition in the medical cannabis space and a cost base that has outpaced the revenue growth.
Vitura’s half year results were below the expectations of shareholders and the Board, with this underperformance carrying through to the full year.
The Year-to-Date (10 months to April 30th), the Company has seen a reduction in gross margin of 6.8 percentage points from FY23 to FY24 and a deterioration of EBITDA margin.
To respond to these challenges, Vitura has already initiated change in the business and is committed to further reducing the cost base by 10% year-on-year The strategy reset has been developed to enable Vitura to return to its strong historic growth, navigate proactively the changing environment, and ensure the Company is in a strong position to leverage the opportunities of a connected and engaged patient, clinician, and partner ecosystem.
Strategic Pillars Vitura’s future is focused on innovating the delivery of healthcare, by building a centralised healthcare experience that connects and enhances each stage of the patient experience and journey throughout their lifetime.
The Company is a proven market leader with reputable partners, offering trusted services to improve patient engagement within the medical industry.
From beginnings as a medical cannabis distribution business, Vitura is now an end-toend healthcare technology company, offering a streamlined healthcare journey for patients from the initial consultation to the prescription, supply, and distribution of medicines – beyond plant-based medications.
The Board and Vitura management have identified four strategic pillars.
1. Strengthen Vitura’s market position: by maintaining its foundational strengths in plant-based medication and nicotine vaping products (subject to special access regulation). Expanding this position to support diversification to deliver what patients want now with the introduction of new verticals including smoking cessation, medicated weight management, and men’s and women’s health.
2. Expand the customer and market base: by increasing customer retention and acquisition through expansion of doctor and clinic networks and extending Vitura’s services through new verticals and B2B partnerships.
3. Technology enhancement: of Doctors on Demand and Canview platforms to provide a best-in-class digital health experience for patients and partners.
4. Financial improvements: by being disciplined around costs and committing to growing multiple revenue streams, each designed to support margin enhancement and improved top- and bottom-line performance.
Each of these pillars is supported by a comprehensive action plan focussed on driving financial and non-financial impacts across the business.
Outlook
Vitura is signalling improvement in its operational and financial performance for FY25 targeting organic growth of at least 10% with new revenue from industry verticals and other initiatives to build from.
The Company is aiming for at least a 3-percentage point improvement on EBITDA margin in FY25, and further EBITDA expansion in FY26. Formal guidance on FY25 performance will be provided at the Full Year Results in August 2024.
Importantly, Vitura expects to establish its position as a leading vertically integrated digital health platform that prioritises the patient journey and adds value to clinicians, pharmacists, and partners along that journey.
The Company has initiated its formal CEO search process and is confident of attracting an experienced leader to execute on this strategy.
Investor Conference Call As part of Mr. Iervasi’s appointment as Chair, the Company has committed to providing a greater level of transparency and communication with its shareholders and will be hosting a series of investor meetings in the coming weeks and months. The Chair will host an investor conference call at 3.00 pm on Friday, 24 May 2024 to provide further details around Vitura’s strategy reset program. Please register via the following link: https://loghic.eventsair.com/755879/216391/Site/Register
i hold VIT
be very afraid .. more than 4 pages and no mention of 'profit or dividend' could become a 'growth hog '
i have a top up order in the market currently ( sub 7.5 cents )
22 MAY 2024
Melbourne, Australia – The Board of Vitura Health Limited (ASX: VIT) (Company), a leading digital health platform business, has today announced that its new Chair, Robert Iervasi, has completed a review of the strategic direction of Vitura.
This review was undertaken by Mr Iervasi since joining the Board in February 2024 in response to the Company’s operational and financial performance, which is currently below the expectations of the Board and Shareholders.
As an outcome of this review, the Board of Vitura has agreed that a reset of the Company’s strategy is required to enable the sustainable growth of Vitura and improve financial performance through diversification and execution excellence.
As part of this reset, Vitura will focus on:
1. Delivery of its vision of offering healthcare platforms that connect patients and physicians at every stage of the healthcare journey from consultation (Doctors on Demand and CDA Clinics) to enabling prescribing and dispensing (Canview) through a growing network of pharmacy partners.
2. Increasing customer retention and acquisition through expansion of its privileged doctor and clinic networks.
3. Extending its offering through new patient care verticals and B2B partnerships.
4. Optimising patient experience to grow lifetime value through increasing the number and volume of services and medications purchased, and driving retention of patients over their lifetime, as well as enhancing the quality-of-service levels to patients.
5. Enhancing the Doctors on Demand and Canview platforms to provide a best-in-class digital health experience for patients and partners. 6. Improving the Company’s financial performance focusing on revenue growth drivers, enhanced margins, and tighter control of the cost base.
The Chair of the Board, Robert Iervasi said: “I am convinced of the significant opportunity we have at Vitura and believe this reset of our strategy will enable a new growth phase for the business and address many of the challenges we’ve experienced so far this financial year. “We are market leaders in many of the categories in which we operate and are on a pathway to further expand our categories and channels to offer an end-to-end digital health business that will capitalise on high-demand patient needs, initially in the areas of smoking cessation, medicated weight loss management, and women’s and men’s health.
“This diversification of our business should enable us to return to a strong growth profile and deliver a truly enhanced healthcare experience to current and prospective patients throughout their lifetimes.
“I look forward to communicating with shareholders to share what is a much clearer and focussed strategy over the coming months.
The fundamentals of Vitura are strong and I have every confidence in the Company’s future success to reach its full potential which we are now well positioned to unlock.”
Environment for change Vitura has operated a successful business for many years delivering strong financial and operational performance.
The foundations of the Vitura business remain solid but overall performance has been eroded because of increased competition in the medical cannabis space and a cost base that has outpaced the revenue growth.
Vitura’s half year results were below the expectations of shareholders and the Board, with this underperformance carrying through to the full year.
The Year-to-Date (10 months to April 30th), the Company has seen a reduction in gross margin of 6.8 percentage points from FY23 to FY24 and a deterioration of EBITDA margin.
To respond to these challenges, Vitura has already initiated change in the business and is committed to further reducing the cost base by 10% year-on-year The strategy reset has been developed to enable Vitura to return to its strong historic growth, navigate proactively the changing environment, and ensure the Company is in a strong position to leverage the opportunities of a connected and engaged patient, clinician, and partner ecosystem.
Strategic Pillars Vitura’s future is focused on innovating the delivery of healthcare, by building a centralised healthcare experience that connects and enhances each stage of the patient experience and journey throughout their lifetime.
The Company is a proven market leader with reputable partners, offering trusted services to improve patient engagement within the medical industry.
From beginnings as a medical cannabis distribution business, Vitura is now an end-toend healthcare technology company, offering a streamlined healthcare journey for patients from the initial consultation to the prescription, supply, and distribution of medicines – beyond plant-based medications.
The Board and Vitura management have identified four strategic pillars.
1. Strengthen Vitura’s market position: by maintaining its foundational strengths in plant-based medication and nicotine vaping products (subject to special access regulation). Expanding this position to support diversification to deliver what patients want now with the introduction of new verticals including smoking cessation, medicated weight management, and men’s and women’s health.
2. Expand the customer and market base: by increasing customer retention and acquisition through expansion of doctor and clinic networks and extending Vitura’s services through new verticals and B2B partnerships.
3. Technology enhancement: of Doctors on Demand and Canview platforms to provide a best-in-class digital health experience for patients and partners.
4. Financial improvements: by being disciplined around costs and committing to growing multiple revenue streams, each designed to support margin enhancement and improved top- and bottom-line performance.
Each of these pillars is supported by a comprehensive action plan focussed on driving financial and non-financial impacts across the business.
Outlook
Vitura is signalling improvement in its operational and financial performance for FY25 targeting organic growth of at least 10% with new revenue from industry verticals and other initiatives to build from.
The Company is aiming for at least a 3-percentage point improvement on EBITDA margin in FY25, and further EBITDA expansion in FY26. Formal guidance on FY25 performance will be provided at the Full Year Results in August 2024.
Importantly, Vitura expects to establish its position as a leading vertically integrated digital health platform that prioritises the patient journey and adds value to clinicians, pharmacists, and partners along that journey.
The Company has initiated its formal CEO search process and is confident of attracting an experienced leader to execute on this strategy.
Investor Conference Call As part of Mr. Iervasi’s appointment as Chair, the Company has committed to providing a greater level of transparency and communication with its shareholders and will be hosting a series of investor meetings in the coming weeks and months. The Chair will host an investor conference call at 3.00 pm on Friday, 24 May 2024 to provide further details around Vitura’s strategy reset program. Please register via the following link: https://loghic.eventsair.com/755879/216391/Site/Register
i hold VIT
be very afraid .. more than 4 pages and no mention of 'profit or dividend' could become a 'growth hog '
i have a top up order in the market currently ( sub 7.5 cents )